This year’s roundtable (in its 15thyear) will focus on metrics + strategies for advancing bioethics, patient-centricity + access to medicines across the bio-pharmaceutical sector and amplifying + connecting participants’ work in these areas. Discussions may inform agenda-setting + metrics development for the Good Pharma Scorecard. Sessions will begin w/ opening remarks + transition to open discussion.Flyer roundtable 2024 2
EY, Yale + Bioethics International’s Annual Pharmaceutical Executive Roundtable on Bioethics, Social Responsibility, Health Equity + the Role of Pharma: Metrics for Success
——————————— Draft Agenda ———————————-
This year’s roundtable will focus on metrics + strategies for advancing bioethics, access to medicines + health equity across the bio-pharmaceutical sector along with amplifying + connecting participants’ work in these areas. Discussions may inform agenda-setting + metrics development for the Good Pharma Scorecard. Sessions will begin w/ opening remarks + transition to open discussion.
———————————-Register here ———————————-
8-8:30am Coffee + Registration
8:30-8:40am Welcome. Jeremy Abbate, Publisher, Scientific American
8:40-8:50 Setting the Stage: Why we are here and what we hope to accomplish. The role of the Good Pharma Scorecard
- Jennifer E. Miller, Co-Director, Yale Program for Bioethical Ethics Associate Professor, Yale School of Medicine, President Bioethics International, CEO Good Pharma Scorecard
8:50-9:35 Transparency, Data sharing, and Health Information Equity in Clinical Research
- Edith Eby, Vice President, Worldwide Medical & Safety, Pfizer or David Leventhal, Pfizer, Data Sharing & Disclosure Lead at Pfizer, Inc., Worldwide Medical & Safety- confirmed
- Takeda person
9:35-9:50 Break
9:50-10:05 Keynote. Marcella Alsan, Professor of Public Policy, Harvard Kennedy School. tbd
10:05-10:50 Diversity, Equity and Fair Inclusion in Clinical Research: Barriers, facilitators + metrics for success
- Martin Mendoza, Director, Health Equity, All of Us Research, NIH
- Esther Krofah, confirming schedule
- Sandy Amaro, Pfizer – confirmed
- Pierre Theodore, Executive Director Health Equity, Genentech – confirmed
- Lilly or JnJ person – via Sommer
- Ricky Farley- via Sommer
10:50-11am Full group input on leading indicators for clinical trial diversity
11-11:50am Access to Medicines in the US: Best practices and metrics for success from drug pricing to patient assistance programs, and beyond
- Moderator: Amrit Ray, Hastings Center, Board Member; Life Sciences Corporate Board Director; Former Global President, R&D and Medical, Pfizer – confirmed
- Seema Verma, General Manager and Senior Vice President at Oracle Corporation, former CMS, checking her calendar
- Samit Hirawat, CMO, BMS – confirmed
- Tom Lee, MD, CMO, Press Ganey – confirmed
- John Wigneswaran, CMO, Walmart – via Esther
- CEO, ICER
- Ashley Valentine – sickle cell – via Esther
11:50-12:10 The Bioethics Leadership Forum
- David Leventhal, Pfizer, Data Sharing & Disclosure Lead at Pfizer, Inc., Worldwide Medical & Safety – confirmed
- Cris Woolston, Sanofi – confirmed
- Missy Heidelberg, Global Bioethics Lead (Director), Takeda – invited
- Meg McKenzie, Genentech, Roche
- Marc Wilenzick, Gilead
- Jessica Scott, CEO, Legacy Health
- Greg Licholai, CMO, ICON
12:10-12:40 Break + grab lunch for working lunch
12:40-1:30pm Fair Access to the Benefits of Research + Medicines and Vaccines in LMICs Hosting Trials
- Steve Pascoe, CMO, CSL Behring – confirmed
- GSK person via Esther
- Moupali Das or Sarah Pruyear, Gilead
- Claudia Carravetta, VP Corporate Responsibility & Global Philanthropy, AbbVie Foundation – exploring rearranging schedule
- Annemarie Galli, Head, Global Medical Affairs Research and Compassionate Use / Managed Access Programs Oncology at GSK
- Lutz Hegemann, President, Global Health & Sustainability, Novartis
1:30-2:20 Patient Engagement in Clinical Research: Metrics for Success
· Amit Sachdev, Chief Patient & External Affairs Officer, Vertex Pharmaceuticals – invited
- Victoria DiBiaso, Global Head, Patient Informed Development & Health Value, Translation, Sanofi – confirmed
- Melissa Penn, Director Patient Engagement R&D, Bayer – confirmed
- Wendy Erler, Global Head Patient Experience, Patient Advocacy & Patient and Caregiver Insights, AstraZeneca – confirmed
- Matt Bryant or Trudy Buckingham, Gilead – inviting
- Kim Sabelko, VP, Scientific Strategy and Programs, Susan G. Komen Foundation person – confirmed
- Ify Osunkwo, MD, MPH, Senior Vice President, Chief Patient Officer, Rare Disease, Novo Nordisk – invited
- Bray Patrick Lake, Senior Digital Health Specialist, FDA invited
2:20-3:10 ESG, Social Impact + Financial Considerations: Can companies do well by doing good?
This panel will explore investor expectations of reporting on the biopharma-specific social dimensions of ESG along with challenges associated with developing standardized metrics. This will also explore the role the Good Pharma Scorecard in driving consistency in reporting on social-responsibility issues in the biopharma innovation portfolio.
- Moderator:
- Lauren Puffer, Director of Sustainability Banking / ESG, Cowen – confirmed
- Trader, CNBC commentator-Via Lauren
- Byron Austin, Head, Corporate Responsibility and ESG Management, Organon
- Jessica Daly, Director, ESG Strategy & Engagement, Merck – confirmed if schedule allows
- Carmen Villar, ESG, Gilead -inviting
- Director of research at a large asset management firm with a healthcare dedicated fund and sustainability focus Via Lauren
- Caitlin Maclean, Milken Financial Innovation Lab
- Claudia Carravetta, Vice President, Corporate Responsibility & President, AbbVie Foundation – invited
3:10-3:45pm Full Group Brainstorming Session on Next Steps
3:45-4pm Closing Remarks
** 4-5pm Bioethics International Board of Directors and Advisors and Bioethics Leadership Council member meeting – members only.
———————————-Register here ———————————-